Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 25788269
Pizzi M, et al. (2015) Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget 6, 6544-52 25788269
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S13-p - CDC37 (human)
Modsite: VWDHIEVsDDEDETH SwissProt Entrez-Gene
Orthologous residues
CDC37 (human): S13‑p, CDC37 (mouse): S13‑p, CDC37 (rat): S13‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, follicular lymphoma
Relevant cell lines - cell types - tissues:  OCI-ly1 (B lymphocyte), OCI-ly10 (B lymphocyte), OCI-ly3 (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
no change compared to control all normal B-cells
increase Increased in all lymphoma cell lines,
silmitasertib decrease in Raji, Oci Ly10, Oci Ly19 DLBCL cell lines
Associated Diseases
Diseases Alterations Comments
B cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, non-Hodgkin's lymphoma increased

S209-p - CK2B (human)
Modsite: QAAsNFksPVktIR_ SwissProt Entrez-Gene
Orthologous residues
CK2B (human): S209‑p, CK2B (mouse): S209‑p, CK2B (rat): S209‑p, CK2B (chicken): S209‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, follicular lymphoma
Relevant cell lines - cell types - tissues:  OCI-ly1 (B lymphocyte), OCI-ly10 (B lymphocyte), OCI-ly3 (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
no change compared to control all normal B-cells
increase Increased in all lymphoma cell lines,
Associated Diseases
Diseases Alterations Comments
B cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, non-Hodgkin's lymphoma increased

S529-p - NFkB-p65 (human)
Modsite: GLPNGLLsGDEDFSs SwissProt Entrez-Gene
Orthologous residues
NFkB‑p65 (human): S529‑p, NFkB‑p65 (mouse): S527‑p, NFkB‑p65 (rat): S528‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, follicular lymphoma
Relevant cell lines - cell types - tissues:  OCI-ly1 (B lymphocyte), OCI-ly10 (B lymphocyte), OCI-ly3 (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silmitasertib decrease in Raji, Oci Ly10, Oci Ly19 DLBCL cell lines